VERAXA Biotech AG (NASDAQ: VRXA) announced the appointment of antibody therapeutics specialist Dr. Christoph Erkel as Chief Scientific Officer, reinforcing the company’s focus on advancing its proprietary BiTAC(R) technology platform. The leadership change comes as VERAXA prepares its lead oncology programs for clinical development, with recent regulatory feedback from Germany’s Paul-Ehrlich-Institute providing additional clarity for the company’s lead BiTAC(R)-TCE program.
Dr. Erkel previously served as Vice President of Research & Development at VERAXA, where he helped oversee development of the company’s antibody therapeutics portfolio. In his new role, he will lead scientific strategy across the BiTAC(R) platforms and broader oncology pipeline while directing efforts to accelerate product candidates toward clinical trials. The company is building a diversified oncology pipeline that includes conditionally active T-cell engagers, bispecific ADCs, and other engineered antibody therapeutics.
The appointment signals VERAXA’s commitment to advancing next-generation immunotherapies that seek to improve efficacy while reducing treatment-related toxicity. Investors are closely monitoring companies developing such therapies, as the field moves toward more targeted cancer treatments with fewer side effects.
VERAXA’s proprietary BiTAC(R) technology platform is designed to create conditionally active bispecific antibodies that engage T cells only within the tumor microenvironment, potentially reducing systemic toxicity. The company’s pipeline includes multiple programs targeting solid tumors, with the lead candidate expected to enter clinical trials soon.
For more information about VERAXA and its latest updates, visit the company’s newsroom at https://ibn.fm/VRXA.
